Royal London Asset Management Ltd. Has $46.99 Million Stake in Bruker Corporation $BRKR

Royal London Asset Management Ltd. cut its position in shares of Bruker Corporation (NASDAQ:BRKR) by 2.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 780,857 shares of the medical research company’s stock after selling 16,195 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Bruker were worth $46,992,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of BRKR. Thrivent Financial for Lutherans grew its stake in Bruker by 561.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after purchasing an additional 152,603 shares during the period. Hantz Financial Services Inc. boosted its holdings in shares of Bruker by 202.7% during the 4th quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company’s stock worth $1,946,000 after buying an additional 27,659 shares in the last quarter. Fifth Third Bancorp grew its position in shares of Bruker by 4,058.3% during the 1st quarter. Fifth Third Bancorp now owns 57,135 shares of the medical research company’s stock worth $2,064,000 after buying an additional 55,761 shares during the period. Franklin Resources Inc. increased its stake in shares of Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after acquiring an additional 1,756,460 shares in the last quarter. Finally, Amundi increased its stake in shares of Bruker by 244.2% in the 1st quarter. Amundi now owns 62,611 shares of the medical research company’s stock valued at $2,261,000 after acquiring an additional 44,421 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $57.08 on Friday. The stock has a market cap of $8.70 billion, a price-to-earnings ratio of -81.54, a PEG ratio of 1.75 and a beta of 1.28. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30. The firm’s 50-day simple moving average is $58.77 and its 200 day simple moving average is $48.00.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s dividend payout ratio is presently -28.57%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several research analyst reports. Guggenheim increased their target price on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Barclays lifted their price target on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. UBS Group set a $60.00 price objective on shares of Bruker in a report on Wednesday, June 24th. TD Cowen reissued a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus set a $50.00 target price on Bruker in a research note on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $56.64.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.